1g9v

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="1g9v" size="450" color="white" frame="true" align="right" spinBox="true" caption="1g9v, resolution 1.85&Aring;" /> '''HIGH RESOLUTION CRY...)
Line 6: Line 6:
==Overview==
==Overview==
The crystal structure of human deoxy hemoglobin (Hb) complexed with a, potent allosteric effector, (2-[4-[[(3,5-dimethylanilino)carbonyl]methyl]phenoxy]-2-methylpropionic, acid) = RSR-13) is reported at 1.85 A resolution. Analysis of the, hemoglobin:effector complex indicates that two of these molecules bind to, the central water cavity of deoxy Hb in a symmetrical fashion, and that, each constrains the protein by engaging in hydrogen bonding and, hydrophobic interactions with three of its four subunits. Interestingly, we also find that water-mediated interactions between the bound effectors, and the protein make significant contributions to the overall binding., Physiologically, the interaction of RSR-13 with Hb results in increased, oxygen delivery to peripheral tissues. Thus, this compound has potential, therapeutic application in the treatment of hypoxia, ischemia, and, trauma-related blood loss. Currently, RSR-13 is in phase III clinical, trials as a radiosensitizing agent in the treatment of brain tumors. A, detailed structural analysis of this compound complexed with deoxy Hb has, important implications for the rational design of future analogs.
The crystal structure of human deoxy hemoglobin (Hb) complexed with a, potent allosteric effector, (2-[4-[[(3,5-dimethylanilino)carbonyl]methyl]phenoxy]-2-methylpropionic, acid) = RSR-13) is reported at 1.85 A resolution. Analysis of the, hemoglobin:effector complex indicates that two of these molecules bind to, the central water cavity of deoxy Hb in a symmetrical fashion, and that, each constrains the protein by engaging in hydrogen bonding and, hydrophobic interactions with three of its four subunits. Interestingly, we also find that water-mediated interactions between the bound effectors, and the protein make significant contributions to the overall binding., Physiologically, the interaction of RSR-13 with Hb results in increased, oxygen delivery to peripheral tissues. Thus, this compound has potential, therapeutic application in the treatment of hypoxia, ischemia, and, trauma-related blood loss. Currently, RSR-13 is in phase III clinical, trials as a radiosensitizing agent in the treatment of brain tumors. A, detailed structural analysis of this compound complexed with deoxy Hb has, important implications for the rational design of future analogs.
 +
 +
==Disease==
 +
Known diseases associated with this structure: Erythremias, alpha- OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141800 141800]], Erythremias, beta- OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141900 141900]], Erythrocytosis OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141850 141850]], HPFH, deletion type OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141900 141900]], Heinz body anemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141850 141850]], Heinz body anemias, alpha- OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141800 141800]], Heinz body anemias, beta- OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141900 141900]], Hemoglobin H disease OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141850 141850]], Hypochromic microcytic anemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141850 141850]], Methemoglobinemias, alpha- OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141800 141800]], Methemoglobinemias, beta- OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141900 141900]], Sickle cell anemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141900 141900]], Thalassemia, alpha- OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141850 141850]], Thalassemia-beta, dominant inclusion-body OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141900 141900]], Thalassemias, alpha- OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141800 141800]], Thalassemias, beta- OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141900 141900]]
==About this Structure==
==About this Structure==
Line 26: Line 29:
[[Category: t state]]
[[Category: t state]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Thu Nov 8 13:02:38 2007''
+
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 17:02:07 2007''

Revision as of 14:55, 12 November 2007


1g9v, resolution 1.85Å

Drag the structure with the mouse to rotate

HIGH RESOLUTION CRYSTAL STRUCTURE OF DEOXY HEMOGLOBIN COMPLEXED WITH A POTENT ALLOSTERIC EFFECTOR

Contents

Overview

The crystal structure of human deoxy hemoglobin (Hb) complexed with a, potent allosteric effector, (2-[4-[[(3,5-dimethylanilino)carbonyl]methyl]phenoxy]-2-methylpropionic, acid) = RSR-13) is reported at 1.85 A resolution. Analysis of the, hemoglobin:effector complex indicates that two of these molecules bind to, the central water cavity of deoxy Hb in a symmetrical fashion, and that, each constrains the protein by engaging in hydrogen bonding and, hydrophobic interactions with three of its four subunits. Interestingly, we also find that water-mediated interactions between the bound effectors, and the protein make significant contributions to the overall binding., Physiologically, the interaction of RSR-13 with Hb results in increased, oxygen delivery to peripheral tissues. Thus, this compound has potential, therapeutic application in the treatment of hypoxia, ischemia, and, trauma-related blood loss. Currently, RSR-13 is in phase III clinical, trials as a radiosensitizing agent in the treatment of brain tumors. A, detailed structural analysis of this compound complexed with deoxy Hb has, important implications for the rational design of future analogs.

Disease

Known diseases associated with this structure: Erythremias, alpha- OMIM:[141800], Erythremias, beta- OMIM:[141900], Erythrocytosis OMIM:[141850], HPFH, deletion type OMIM:[141900], Heinz body anemia OMIM:[141850], Heinz body anemias, alpha- OMIM:[141800], Heinz body anemias, beta- OMIM:[141900], Hemoglobin H disease OMIM:[141850], Hypochromic microcytic anemia OMIM:[141850], Methemoglobinemias, alpha- OMIM:[141800], Methemoglobinemias, beta- OMIM:[141900], Sickle cell anemia OMIM:[141900], Thalassemia, alpha- OMIM:[141850], Thalassemia-beta, dominant inclusion-body OMIM:[141900], Thalassemias, alpha- OMIM:[141800], Thalassemias, beta- OMIM:[141900]

About this Structure

1G9V is a Protein complex structure of sequences from Homo sapiens with SO4, HEM and RQ3 as ligands. Full crystallographic information is available from OCA.

Reference

High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector., Safo MK, Moure CM, Burnett JC, Joshi GS, Abraham DJ, Protein Sci. 2001 May;10(5):951-7. PMID:11316875

Page seeded by OCA on Mon Nov 12 17:02:07 2007

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools